Rajanikanth Madabushi

Rajanikanth Madabushi

Auto-generated profile, based on publicly available information

Rajanikanth Madabushi

U.S. Food and Drug Administration

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SHSudharshan Hariharan
Sudharshan Hariharan
RMRajanikanth Madabushi
Rajanikanth Madabushi

1 February 2008 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
YWYaning Wang
Yaning Wang
ABA. Venkatesh Bhattaram
A. Venkatesh Bhattaram
PJPravin R. Jadhav
Pravin R. Jadhav
LLLawrence J. Lesko
Lawrence J. Lesko
RMRajanikanth Madabushi
Rajanikanth Madabushi
JGJogarao V. S. Gobburu
Jogarao V. S. Gobburu

1 January 2011 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
RMRajanikanth Madabushi
Rajanikanth Madabushi
DCDonna S. Cox
Donna S. Cox
MHMohammad Hossain
Mohammad Hossain
DBDuane A. Boyle
Duane A. Boyle
BPBela R. Patel
Bela R. Patel
JGJogarao V. S. Gobburu
Jogarao V. S. Gobburu

23 December 2018 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PDF file
RMRajanikanth Madabushi
Rajanikanth Madabushi
YWYaning Wang
Yaning Wang
IZIssam Zineh
Issam Zineh
Model‐informed drug development (MIDD) has recently garnered much attention as a potential enabler of efficient drug development. In their recent article, Jain et al. describe barriers and opportunities to achieve the full potential of MIDD. The authors point out well‐accepted and promising new applications of MIDD in drug development and regulatory evaluation. There is arguably a greater appreciation of the benefits and promise of MIDD now more than ever. As noted by the authors, this is reflected by the inclusion of MIDD‐related performance goals in the latest congressionally reauthorized Prescription Drug User Fee Act (PDUFA) VI. Against this backdrop, the key question is how we capitalize on this unique opportunity to advance MIDD.

9 May 2012 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
YJYuyan Jin
Yuyan Jin
RBRobert R. Bies
Robert R. Bies
MGMarc R. Gastonguay
Marc R. Gastonguay
NSNorman Stockbridge
Norman Stockbridge
JGJogarao Gobburu
Jogarao Gobburu
RMRajanikanth Madabushi
Rajanikanth Madabushi

5 July 2014 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SHSudharshan Hariharan
Sudharshan Hariharan
MSMary Ross Southworth
Mary Ross Southworth
RMRajanikanth Madabushi
Rajanikanth Madabushi
Click on the article title to read more.